ESMO Precision Medicine Working Group released NGS recommendations

ESMO shared on LinkedIn:

“ESMO has just released recommendations for the use of next-generation sequencing (NGS) for patients with Advanced Cancer and some Rare Cancers developed by the ESMO Precision Medicine Working Group.
Building on the first recommendations released in 2020, the updated version delves into the clinical impact of tumour NGS, using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) to consider factors like cost-effectiveness and accessibility.
ESMO also recommends NGS to detect tumour-agnostic alterations in patients with metastatic cancers, particularly when matched therapies are available.
To learn more about this topic, read the ESMO Daily Reporter article.”

Video attached to the post.
Source: ESMO/LinkedIn